Randomized Phase II trial of Cyclophosphamide and the Oral Poly (ADP-ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer

BACKGROUND: In tumors carrying BRCA mutations, DNA damage caused by standard cytotoxic chemotherapy can be potentiated by poly [ADP-ribose] polymerase (PARP) inhibitors, leading to increased cell death through synthetic lethality. Individuals carrying mutations in BRCA have an increased incidence of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Invest New Drugs
Main Authors: Kummar, Shivaani, Wade, James L., Oza, Amit M., Sullivan, Daniel, Chen, Alice P., Gandara, David R., Ji, Jiuping, Kinders, Robert J., Wang, Lihua, Allen, Deborah, Coyne, Geraldine O’Sullivan, Steinberg, Seth M., Doroshow, James H.
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4860030/
https://ncbi.nlm.nih.gov/pubmed/26996385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0335-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker